Pharming Group マネジメント

マネジメント基準チェック /24

Pharming Groupの CEO はSimon de Vriesで、 Nov2008年に任命され、の在任期間は 16.08年です。の年間総報酬は$ 2.81Mで、 24%給与と76%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の2.13%を直接所有しており、その価値は€ 10.48M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と3.7年です。

主要情報

Simon de Vries

最高経営責任者

US$2.8m

報酬総額

CEO給与比率	24.0%
CEO在任期間	16yrs
CEOの所有権	2.1%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	3.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Pharming Group の収益と比較して、Simon de Vries の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$18m
Jun 30 2024	n/a	n/a	-US$13m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$673k	-US$11m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$2m	US$636k	US$14m
Sep 30 2022	n/a	n/a	US$30m
Jun 30 2022	n/a	n/a	US$21m
Mar 31 2022	n/a	n/a	US$11m
Dec 31 2021	US$3m	US$681k	US$16m
Sep 30 2021	n/a	n/a	US$22m
Jun 30 2021	n/a	n/a	US$31m
Mar 31 2021	n/a	n/a	US$37m
Dec 31 2020	US$3m	US$614k	US$38m
Sep 30 2020	n/a	n/a	US$44m
Jun 30 2020	n/a	n/a	US$46m
Mar 31 2020	n/a	n/a	US$42m
Jan 01 2020	n/a	n/a	US$41m
Sep 30 2019	n/a	n/a	US$38m
Jun 30 2019	n/a	n/a	US$34m
Mar 31 2019	n/a	n/a	US$29m
Dec 31 2018	US$2m	US$579k	US$29m
Sep 30 2018	n/a	n/a	-US$29m
Jun 30 2018	n/a	n/a	-US$44m
Mar 31 2018	n/a	n/a	-US$80m
Dec 31 2017	US$2m	US$537k	-US$91m

報酬と市場: Simonの総報酬 ($USD 2.81M ) は、 UK市場 ($USD 995.46K ) の同規模の企業の平均を上回っています。

報酬と収益: Simonの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Simon de Vries (65 yo)

16yrs

在職期間

US$2,809,000

報酬

Dr. Sijmen De Vries, also known as Simon, M. D., M. B.A., has been the Chief Executive Officer of Pharming Group N. V. since November 03, 2008 and also serves as its Executive Director since October 13, 20...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sijmen de Vries	President	16yrs	US$2.81m	2.13% € 10.5m
Jeroen Wakkerman	Chief Financial Officer	4yrs	データなし	0.064% € 312.1k
Mireille Sanders	Chief Operations Officer	5.3yrs	データなし	0.12% € 578.9k
Susanne Embleton	Investor Relations Manager	no data	データなし	データなし
Ruud Van Outersterp	Chief Ethics & Compliance Officer	3.5yrs	データなし	0.024% € 119.7k
Anurag Relan	Chief Medical Officer	3.4yrs	データなし	0.027% € 133.5k
Stephen Toor	Chief Commercial Officer & GM Americas	7.8yrs	データなし	0.028% € 136.0k
Alexander Breidenbach	Chief Business Officer	1.2yrs	データなし	0.0096% € 47.3k
Bruno M. Giannetti	Consultant	3.4yrs	データなし	データなし

3.8yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: 0QCOの経営陣は経験豊富であると考えられます ( 3.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Sijmen de Vries	President	16.1yrs	US$2.81m	2.13% € 10.5m
Leonard Kruimer	Independent Non-Executive Director	3.5yrs	US$90.00k	0.018% € 87.8k
Mark Pykett	Independent Non-Executive Director	3.9yrs	US$87.00k	0.022% € 105.8k
Deborah Jorn	Independent Non-Executive Vice-Chairperson	5.5yrs	US$87.00k	0.024% € 117.1k
Steven Baert	Independent Non-Executive Director	3.5yrs	US$90.00k	0.018% € 87.8k
Barbara Yanni	Independent Non-Executive Director	3.9yrs	US$94.00k	0.022% € 105.8k
Richard Peters	Non-Executive Chairman of Board	1.2yrs	US$46.00k	0.0093% € 45.6k
Jabine van der Meijs	Independent Non-Executive Director	3.5yrs	US$94.00k	0.018% € 87.8k

3.7yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: 0QCOの取締役会は経験豊富であると考えられます ( 3.7年の平均在任期間)。

Pharming Group マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insufficient new directors

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

High number of new directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Insufficient new directors

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 26%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Now 20% undervalued

Now 22% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings released: EPS: US$0.014 (vs US$0 in 3Q 2021)

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

First quarter 2022 earnings released: EPS: US$0.005 (vs US$0.013 in 1Q 2021)

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

High number of new directors

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome

Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe

Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST®

Second quarter 2021 earnings released: EPS €0.008 (vs €0.016 in 2Q 2020)

Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome

Independent Non-Executive Director has left the company

Independent Non-Executive Director has left the company

First quarter 2021 earnings released: EPS €0.011 (vs €0.013 in 1Q 2020)

Full year 2020 earnings released: EPS €0.052 (vs €0.058 in FY 2019)

Executive Director & CEO recently bought €489k worth of stock

Pharming Group N.V. to Report Fiscal Year 2020 Final Results on Apr 06, 2021

Full year 2020 earnings released: EPS €0.051 (vs €0.058 in FY 2019)

Revenue beats expectations

Pharming Group N.V. to Report First Half, 2021 Results on Aug 05, 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €1.21

Pharming Group N.V. Announces Board Appointments

Revenue misses expectations

Third quarter 2020 earnings released: EPS €0.011

Market bids up stock over the past week

New 90-day high: €1.19

マネジメント基準チェック /24